TGS | Jotup

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Retrieved on:

Saturday, April 6, 2024

MB, TGS, High, Science, CH.B, Risk, Research, American College, MACE, Professional corporation, IPE, JACC, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular Events) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as reducing the risk of cardiovascular (CV) events in patients irrespective of baseline LDL-C level. The REDUCE-IT analysis results relating Lp(a) concentrations with CV risk were also published online today in the Journal of the American College of Cardiology (JACC).

Key Points:

There are no treatments currently approved to reduce residual CV risk on top of contemporary medical therapy in patients with high Lp(a) levels.
In this subanalysis, there were 7,026 REDUCE-IT patients with baseline Lp(a) data and a median Lp(a) value of 11.6 (Q1-Q3: 5.0-37.4) mg/dL.
Importantly, the treatment benefit of IPE was evident across subgroups with both high (≥50 mg/dL) and low (
Limitations are that randomization was not stratified by baseline LDL-C, however, baseline characteristics were similar among the two baseline LDL-C subgroups.

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

Retrieved on:

Sunday, April 7, 2024

TGS, AP, Ionis, Incidence, Abdominal pain, IONS, Webcast, Patient, NEJM, Fasting, American College, Ionis Pharmaceuticals, FCS, ACC, Triglyceride, Annual general meeting, Medicine, Pharmaceutical industry

CARLSBAD, Calif., April 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis' lead independent investigational medicine, olezarsen, for the treatment of adults with familial chylomicronemia syndrome (FCS). The olezarsen 80 mg monthly dose met the primary endpoint of significantly reducing triglycerides (TGs) in patients with genetically validated FCS at six months. In addition, olezarsen demonstrated robust and sustained reductions in TGs and serum apolipoprotein C-III (apoC-III) levels. Importantly, olezarsen reduced the incidence of acute pancreatitis (AP) events over the 12-month treatment period compared to placebo. Olezarsen also demonstrated a favorable safety and tolerability profile. These results were presented in an oral presentation at the 2024 American College of Cardiology (ACC) Annual Meeting in Atlanta, Georgia and published simultaneously in The New England Journal of Medicine (NEJM). Based on these data, Ionis is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.

Key Points:

Based on these data, Ionis is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.
In the study, patients were treated with olezarsen 80 mg (n=22), 50 mg (n=21) or placebo (n=23) once every four weeks.
Serious AEs occurred in 14% of patients treated with olezarsen 80 mg, 19% treated with olezarsen 50 mg, and 39% treated with placebo.
Ionis will host a webcast to discuss the detailed results from the Balance study on Monday, April 8 at 10:00 am ET.

New Industry Report Asks Whether 2024 is Living Up to Expectations for Offshore Wind?

Retrieved on:

Thursday, March 21, 2024

Research, AR6, Farm, Growth, Q1, Intelligence, Wind, Investment, TGS, Professional, Renewable energy

The Q1 report looks at whether 2024 is still expected to deliver on that promise.

Key Points:

The Q1 report looks at whether 2024 is still expected to deliver on that promise.
In 2023 the global offshore wind sector fully commissioned 7 GW, and this has been followed by 592 MW in Q1 2024.
Additionally, the report noted that 2024 is poised to witness a surge in corporate power purchase agreements (PPAs).
TGS releases regular intelligence reports on a wide variety of offshore energy subjects, powered by 4C Offshore market intelligence.

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

Retrieved on:

Tuesday, March 12, 2024

This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.

Key Points:

This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.
Since its inception in September 2021, the TGS program has demonstrated its ability to serve as an early detection mechanism for new pathogens and fill gaps in global biosurveillance.
In October 2023, the program expanded to cover a list of more than 30 viral and bacterial targets.
“We are thrilled to have the opportunity to take the TGS program to the next level.

The Gathering Spot Celebrates 8 Years with Major Expansion in Houston and New Tech Launch

Retrieved on:

Wednesday, March 20, 2024

Bank of America, Culture, Sport, CFO, TK, Nike, Bank, Club, LeBron James, TGS, Nightclub

TGS will establish its fourth physical location in Houston, Texas, joining the ranks of its thriving Atlanta, Washington D.C., and Los Angeles clubs.

Key Points:

TGS will establish its fourth physical location in Houston, Texas, joining the ranks of its thriving Atlanta, Washington D.C., and Los Angeles clubs.
The announcement of the new club location comes when TGS's influence has never been more palpable.
In tandem with the expansion into Houston, TGS will enhance its member experience by launching its mobile app at the end of March.
For more information about The Gathering Spot or to request an invitation for membership, visit https://thegatheringspot.club/ .

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

Retrieved on:

Tuesday, March 12, 2024

BOSTON, March 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of onsite pathogen screening, today announced they are expanding the CDC's Traveler-based Genomic Surveillance program (TGS) to new collection locations at US international airports in Miami (MIA) and Chicago (ORD).

Key Points:

This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.
In October 2023, the program expanded to cover a list of more than 30 viral and bacterial targets.
We are honored that CDC continues to trust this consortium to deliver a strategic piece of our biothreat preparedness."
"The additional funding of the program allows us to add infrastructure to support new mobile testing centers at Miami International Airport and Chicago O'Hare International Airport.

New Slate of Officers and Board Members Elected at EnerGeo’s 53rd Annual Membership Meeting

Retrieved on:

Thursday, February 22, 2024

Ex officio member, EVP, Exploration, TGS, CGG, Woodside Energy, Shearwater, SLB, PGS, Breakthrough Institute, CNCP, Energy, Fairfield Geotechnologies, Independent, Management

Houston, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Today, EnerGeo Alliance successfully concluded its 53rd Annual Membership Meeting where members elected new directors and officers.

Key Points:

Houston, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Today, EnerGeo Alliance successfully concluded its 53rd Annual Membership Meeting where members elected new directors and officers.
Andrea Lovatini (Director, Exploration Data and Geosolutions, slb) and Irene Waage Basili (CEO, Shearwater ) have been elected directors for 2-year terms (2024-2026).
The virtual EnerGeo Alliance Annual Membership Meeting featured keynote speakers Dr. Vijaya Ramachandran , Director for Energy and Development at The Breakthrough Institute and Cameron Grebe , IOPER (International Offshore Petroleum Environment Regulators) Chair.
Industry executives Irene Waage Basili (CEO, Shearwater) and Andy Drummond (EVP, Exploration & Development, Woodside Energy ) shared their perspectives on the industry’s future.

New Fortress Energy Places Terminal Gas Sul LNG Terminal in Santa Catarina, Brazil into Operation

Retrieved on:

Friday, March 1, 2024

Other Energy, Maritime, Utilities, Logistics, Supply Chain Management, Oil, Gas, Transport, Energy, FSRU, TGS, Arno Drescher, Wes Edens, Peptide

New Fortress Energy, Inc. (Nasdaq: NFE) (“NFE” or the “Company”) today announced that its Terminal Gas Sul (“TGS”) LNG terminal located in Santa Catarina, Brazil, is now operational with the Energos Winter Floating Storage Regasification Unit (FSRU) on-site.

Key Points:

New Fortress Energy, Inc. (Nasdaq: NFE) (“NFE” or the “Company”) today announced that its Terminal Gas Sul (“TGS”) LNG terminal located in Santa Catarina, Brazil, is now operational with the Energos Winter Floating Storage Regasification Unit (FSRU) on-site.
TGS is an offshore LNG import terminal with a capacity of approximately 6 MTPA (300 TBtu) and maximum send out of 500 mmscf/day.
The terminal includes the Winter FSRU and a 33-kilometer, 20-inch pipeline, which connects the facility to the existing inland Transportadora Brasileira Gasoduto Bolívia-Brasil (“TBG”) pipeline.
The TGS terminal is essential infrastructure and will play a vital role in meeting the region's power and gas requirements.

Telefónica and Lynk successfully demonstrate Sat2Phone technology for the first time in Argentina

Retrieved on:

Monday, February 26, 2024

IOT (Internet of Things), Technology, Satellite, Mobile, Wireless, Telecommunications, Internet, Internet of things, Movistar, TGS, Mobile phone

Lynk Global, Inc. (Lynk) , the world’s leading satellite direct-to-mobile phone (Sat2Phone) services provider, today announced that it has successfully tested for the first time in Argentina its patented and proven Sat2Phone technology with Telefónica through its business units Telefónica Argentina and Telefónica Global Solutions (TGS) .

Key Points:

Lynk Global, Inc. (Lynk) , the world’s leading satellite direct-to-mobile phone (Sat2Phone) services provider, today announced that it has successfully tested for the first time in Argentina its patented and proven Sat2Phone technology with Telefónica through its business units Telefónica Argentina and Telefónica Global Solutions (TGS) .
Lynk’s Sat2Phone technology could enable Telefónica to offer its subscribers enhanced geographic coverage, including extending rural coverage in areas where it is nearly impossible to deploy terrestrial telecommunications infrastructure, such as jungles or mountainous areas.
In addition, the Sat2Phone technology could be used as a back-up to ensure service resilience and provide always-on connectivity to IoT networks.
Daniel Dooley, Chief Commercial Officer of Lynk, said, "We are very excited to be demonstrating the capabilities of Sat2Phone with Telefónica in Patagonia, one of the most remote regions in the world.

Ginkgo Biosecurity Launches Doha-Based Pathogen Monitoring Center, CUBE-D, Establishing Middle East Hub for Global Bioradar, at Qatar Free Zones

Retrieved on:

Tuesday, February 27, 2024

DOHA, Qatar, Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has announced today the signing of an agreement with Qatar Free Zones Authority (QFZ) and Doha Venture Capital (DVC) to build the first Center for Unified Biosecurity Excellence in Doha (CUBE-D) within Qatar Free Zones. The signing took place alongside QFZ's and DVC's participation in the Web Summit Qatar, in a ceremony attended by HE. Dr. Ahmad Al-Sayed, Minister of State and Chairman of QFZ/DVC, HE. Mohammed bin Ali Al Mannai, Minister of Communications and Information Technology (MCIT) and Vice Chairman of QFZ/DVC, and Matthew McKnight, General Manager for Biosecurity, Ginkgo Bioworks, along with executives from the ministry and the three signing entities.

Key Points:

The signing took place alongside QFZ's and DVC's participation in the Web Summit Qatar, in a ceremony attended by HE.
CUBE-D's advanced platform is expected to serve as a nucleus for global pathogen monitoring efforts and be a key hub in Ginkgo's bioradar network.
I am proud of Ginkgo's ability to technically and socially synthesize this global immune system, one node and hub at a time.
Matthew McKnight, General Manager of Biosecurity at Ginkgo Bioworks: "CUBE-D represents the next generation of biosecurity infrastructure.